Meropenem Generis

Meropenem Trihydrate, the active ingredient in Meropenem Generis, is a carbapenem presented as an intravenous formulation for injection use. It treats severe bacterial infections, including intra‑abdominal, urinary, respiratory, bloodstream, and central nervous system infections, in hospitalized patients. GNH USA supplies Meropenem Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem Generis is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by susceptible bacteria. - Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: eradicates resistant Gram‑negative and some Gram‑positive organisms. - Hospital‑acquired pneumonia: effective against common nosocomial respiratory pathogens. - Ventilator‑associated pneumonia: covers multidrug‑resistant organisms in ventilated patients. - Septicemia: rapidly clears bloodstream infections caused by susceptible bacteria. - Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis.

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional episodes during infusion. - Headache: transient and usually resolves. - Rash: mild erythematous skin reactions. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile‑associated diarrhea: may develop after therapy. - Thrombocytopenia: reduced platelet count, monitor labs. - Nephrotoxicity: worsening renal function in susceptible individuals. - Neutropenia: decreased neutrophil count, monitor blood counts.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for adverse events. - Renal function: adjust dose in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactams. - Seizure risk: monitor closely in patients with a history of seizures or CNS disorders. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications for possible interactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Valproic acid: meropenem can markedly reduce serum valproate levels, increasing seizure risk. - Cisplatin: concurrent use may enhance nephrotoxic effects. - Loop diuretics: combined therapy can exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Vancomycin: increased risk of renal dysfunction; adjust dosing as needed. - Warfarin: may affect INR; frequent coagulation monitoring is advised.